You are here

  • Home
  • Archive
  • Volume 17, Issue 1
  • Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events

Article Text

Article menu
Download PDFPDF
Prognosis
Cohort study
Patients treated with aspirin after a first myocardial infarction who also receive a proton pump inhibitor have a higher incidence of cardiovascular events
  1. David N Juurlink
  1. Department of Clinical Epidemiology, Sunnybrook Research Institute, University of Toronto and The Institute for Clinical Evaluative Sciences, Toronto, Canada
  1. Correspondence to David N Juurlink
    Department of Clinical Epidemiology, Sunnybrook Research Institute, University of Toronto and The Institute for Clinical Evaluative Sciences, G Wing 106 (ICES), Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada; dnj{at}ices.on.ca

https://doi.org/10.1136/ebmed.2011.100263

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Charlot M, Grove EL, Hansen PR, et al. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. BMJ 2011;342:d2690.OpenUrlAbstract/FREE Full Text

    Context

    Proton pump inhibitors (PPIs) block the final step in gastric acid production, increasing intragastric pH from about 1 to above 4, depending on the agent and dose used.1 This increase may influence the fate of drugs in the stomach. In the case of acetylsalicylic acid (ASA), neutralisation of gastric contents significantly decreases the absorption of both ASA and salicylic acid,2 but the clinical significance of this is uncertain. While lansoprazole does not influence the effect of low-dose enteric-coated ASA on …

    View Full Text

    Footnotes

    • Competing interests None.